Angiotensin-Converting Enzyme Inhibitor Dose Optimization and Its Associated Factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia

References

• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239. doi:10.1016/j.jacc.2013.05.019
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• McMurray JJJV. Improving outcomes in heart failure: a personal perspective†. Eur Heart J. 2015;36(48):3467–3470. doi:10.1093/eurheartj/ehv565
   PubMed Web of Science ®Google Scholar
• Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11. doi:10.15420/cfr.2016:25:2
   PubMedGoogle Scholar
• Agbor VN, Essouma M, Ntusi NAB, Nyaga UF, Bigna JJ, Noubiap JJ. Heart failure in sub-Saharan Africa: A contemporaneous systematic review and meta-analysis. Int J Cardiol. 2018;257:207–215. doi:10.1016/j.ijcard.2017.12.048
   Google Scholar
• Widmer F. [Comorbidity in heart failure]. Ther Umsch. 2011;68(2):103–106. German. doi:10.1024/0040-5930/a000127
   PubMedGoogle Scholar
• Lawson CA, Solis-Trapala I, Dahlstrom U, et al. Comorbidity health pathways in heart failure patients: a sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish heart failure registry. PLoS Med. 2018;15:e1002540. doi:10.1371/journal.pmed.1002540
   PubMed Web of Science ®Google Scholar
• Sleiman O, Ghanem W, Murin J. Angiotensin-converting enzyme inhibitors: do we utilize our knowledge in heart failure patients? J Clin Basic Cardiol. 2001;4(4):279–283.
   Google Scholar
• Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–1848. doi:10.1016/S0140-6736(09)61913-9
   PubMed Web of Science ®Google Scholar
• Cowie MR, Schöpe J, Wagenpfeil S, et al. Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Fail. 2021;8(2):861–871. doi:10.1002/ehf2.13237
   PubMed Web of Science ®Google Scholar
• Wang -C-C, Wu C-K, Tsai M-L, et al. 2019 Focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure. Acta Cardiol Sin. 2019;35(3):244–283. doi:10.6515/ACS.201905_35(3).20190422A
   PubMed Web of Science ®Google Scholar
• Massie BM, Armstrong PW, Cleland JG, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Arch Intern Med. 2001;161(2):165–171. doi:10.1001/archinte.161.2.165
   PubMedGoogle Scholar
• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–1146. doi:10.1136/hrt.2003.025270
   PubMed Web of Science ®Google Scholar
• Simpson CR, Lewsey JD, Stewart S, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 millionpeople.Circulation. 2009;119:515–523. doi:10.1161/CIRCULATIONAHA.108.812172
   PubMed Web of Science ®Google Scholar
• Gibbs C, Lip G, Beevers D. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol. 1999;48(6):861. doi:10.1046/j.1365-2125.1999.00093.x
   PubMed Web of Science ®Google Scholar
• Chen Y-T, Wang Y, Radford MJ, Krumholz HM. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J. 2001;141(3):410–417. doi:10.1067/mhj.2001.113227
   PubMed Web of Science ®Google Scholar
• Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL Jr. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol. 2000;86(5):519–523. doi:10.1016/S0002-9149(00)01005-5
   PubMed Web of Science ®Google Scholar
• Barywani SB, Ergatoudes C, Schaufelberger M, Petzold M, Fu ML. Does the target dose of neurohormonal blockade matter for outcome in systolic heart failure in octogenarians? Int J Cardiol. 2015;187:666–672. doi:10.1016/j.ijcard.2015.03.428
   PubMed Web of Science ®Google Scholar
• Sweileh WM, Sawalha AF, Rinno TM, Zyoud S, Al-Jabi SW. Optimal dosing of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: a cross-sectional study in Palestine. Ann Saudi Med. 2009;29(2):119–122. doi:10.4103/0256-4947.51794
   PubMed Web of Science ®Google Scholar
• Solal AC, Leurs I, Assyag P, et al. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey. Arch Cardiovasc Dis. 2012;105(6–7):355–365. doi:10.1016/j.acvd.2012.04.003
   PubMed Web of Science ®Google Scholar
• Schmidt S, Hürlimann D, Starck CT, et al. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Eur Heart J. 2014;35(16):1051–1060. doi:10.1093/eurheartj/eht514
   PubMed Web of Science ®Google Scholar
• Niriayo YL, Kumela K, Gidey K, Angamo MT. Utilization and dose optimization of angiotensin-converting enzyme inhibitors among heart failure patients in Southwest Ethiopia. Biomed Res Int. 2019;2019:9463872. doi:10.1155/2019/9463872
   PubMed Web of Science ®Google Scholar
• Atey TM, Teklay T, Asgedom SW, Mezgebe HB, Teklay G, Kahssay M. Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in ayder comprehensive specialized hospital: a cross-sectional study. BMC Res Notes. 2018;11(1):209. doi:10.1186/s13104-017-2820-5
   PubMedGoogle Scholar
• O’brien RM. A caution regarding rules of thumb for variance inflation factors. Qual Quant. 2007;41(5):673–690. doi:10.1007/s11135-006-9018-6
   Web of Science ®Google Scholar
• Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Vol. 398. John Wiley & Sons; 2013.
   Google Scholar
• Komajda M, Boehm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis. Eur J Heart Fail. 2018;20(9):1315–1322. doi:10.1002/ejhf.1234
   PubMed Web of Science ®Google Scholar
• Rochon PA, Sykora K, Bronskill SE, et al. Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community. J Gen Intern Med. 2004;19(6):676–683. doi:10.1111/j.1525-1497.2004.30328.x
   PubMed Web of Science ®Google Scholar
• Kojima N, Williams JM, Slaughter TN, et al. Renoprotective effects of combined SGLT 2 and ACE inhibitor therapy in diabetic D ahl S rats. Physiol Rep. 2015;3(7):e12436. doi:10.14814/phy2.12436
   PubMedGoogle Scholar
• Chang HY, Wang CC, Wei J, et al. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: results from TSOC-HFrEF registry. J Chin Med Assoc. 2017;80(12):750–757. doi:10.1016/j.jcma.2017.04.011
   PubMed Web of Science ®Google Scholar
• Komajda M, Lutiger B, Madeira H, et al. Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail. 2004;6(4):467–475. doi:10.1016/j.ejheart.2003.12.019
   PubMed Web of Science ®Google Scholar
• Gotsman I, Rubonivich S, Azaz-Livshits T. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome. Isr Med Assoc J. 2008;10(3):214–218.
   PubMed Web of Science ®Google Scholar
• Lonn E. Dose response of ACE inhibitors: implications of the SECURE trial. Trials. 2001;2(4):155. doi:10.1186/CVM-2-4-155
   Web of Science ®Google Scholar
• Komajda M, Anker SD, Cowie MR, et al. Physicians’ adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514–522. doi:10.1002/ejhf.510
   PubMed Web of Science ®Google Scholar
• Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T. General practitioners’ adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol. 2016;105(5):441–450. doi:10.1007/s00392-015-0939-8
   PubMed Web of Science ®Google Scholar
• Cowie MR, Komajda M. Quality of physician adherence to guideline recommendations for life-saving treatment in heart failure: an international survey. Card Fail Rev. 2017;3(2):130. doi:10.15420/cfr.2017:13:1
   PubMedGoogle Scholar
• Sargento L, Simões AV, Longo S, Lousada N, Dos Reis RP. Treatment with optimal dose angiotensin-converting enzyme inhibitors/angiotensin receptor blockers has a positive effect on long-term survival in older individuals (aged> 70 years) and octogenarians with systolic heart failure. Drugs Aging. 2016;33(9):675–683. doi:10.1007/s40266-016-0393-y
   PubMed Web of Science ®Google Scholar
• Gianni M, Bosch J, Pogue J, et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J. 2007;28(11):1382–1388. doi:10.1093/eurheartj/ehm017
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am J Med. 2010;123(11):1016–1030. doi:10.1016/j.amjmed.2010.06.014
   PubMed Web of Science ®Google Scholar
• Raebel M. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2011;30:e156–166. doi:10.1111/j.1755-5922.2010.00258.x
   PubMed Web of Science ®Google Scholar
• Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors. Am J Cardiovasc Drugs. 2012;12(4):263–277. doi:10.1007/BF03261835
   PubMed Web of Science ®Google Scholar
• Ter Maaten JM, Martens P, Damman K, et al. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol. 2020;109(8):1048–1059. doi:10.1007/s00392-020-01598-w
   PubMed Web of Science ®Google Scholar
• Jessup M, Abraham WT, Casey DE, et al; 2009 Writing Group to Review New Evidence and Update the 2005 Guideline for the Management of Patients with Chronic Heart Failure Writing on Behalf of the 2005 Heart Failure Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016. doi:10.1161/CIRCULATIONAHA.109.192064
   PubMed Web of Science ®Google Scholar